Literature DB >> 1675892

High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients.

H J Coppens1, C J Slooff, A M Paans, T Wiegman, W Vaalburg, J Korf.   

Abstract

We investigated whether the lack of therapeutic response to long-term and adequate neuroleptic treatment was due to a failure to achieve a blockade of cerebral dopamine receptors. Six chronic schizophrenic and medicated patients (DSM-III-R diagnosis, paranoid or disorganized type) were assessed with the Present State Examination and the Brief Psychiatric Rating Scale. According to the Chouinard Rating Scale there were little extrapyramidal symptoms, although no anticholinergic drugs were given. Plasma levels of the neuroleptics were determined and found in the therapeutic range or higher. Dopamine D2-receptor occupancy was determined with positron emission tomography using 11C-methylspiperone as ligand. There was a more than 95% blockade of the D2 receptors in the striatum. These results indicate that the lack of therapeutic response and extra-pyramidal side effects cannot be attributed to an incomplete blockade of cerebral D2 receptors and that the pathogenetic role of these receptors can be questioned in therapy-resistant schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675892     DOI: 10.1016/0006-3223(91)90132-6

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  15 in total

1.  A method to estimate in vivo D2 receptor occupancy by antipsychotic drugs.

Authors:  R A Roemer; E Richelson; C Shagass; L Leventhal
Journal:  J Psychiatry Neurosci       Date:  1996-11       Impact factor: 6.186

Review 2.  Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

Authors:  Shinichiro Nakajima; Hiroyoshi Takeuchi; Eric Plitman; Gagan Fervaha; Philip Gerretsen; Fernando Caravaggio; Jun Ku Chung; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Res       Date:  2015-02-13       Impact factor: 4.939

Review 3.  Factors associated with response to clozapine in schizophrenia: a review.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Haruo Kashima
Journal:  Psychopharmacol Bull       Date:  2011

Review 4.  Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.

Authors:  Frederick C Nucifora; Edgar Woznica; Brian J Lee; Nicola Cascella; Akira Sawa
Journal:  Neurobiol Dis       Date:  2018-08-29       Impact factor: 5.996

Review 5.  Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.

Authors:  Emma Perez-Costas; Miguel Melendez-Ferro; Rosalinda C Roberts
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

6.  Behavioral adaptation in C. elegans produced by antipsychotic drugs requires serotonin and is associated with calcium signaling and calcineurin inhibition.

Authors:  Dallas R Donohoe; Raymond A Jarvis; Kathrine Weeks; Eric J Aamodt; Donard S Dwyer
Journal:  Neurosci Res       Date:  2009-04-05       Impact factor: 3.304

7.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

8.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

9.  Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response.

Authors:  Rosalinda C Roberts; Joy K Roche; Robert R Conley; Adrienne C Lahti
Journal:  Synapse       Date:  2009-06       Impact factor: 2.562

Review 10.  D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status.

Authors:  R Schlösser; S Schlegel
Journal:  J Neural Transm Gen Sect       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.